(III) Modulating metabolism remodeling to drive therapy resistance: MSCs have been found to upregulate gastric cancer cell expression of NPRA, thus increasing FAO activity to resist cisplatin therapy [192]. This evidence concerns the gene NPR1 and gastric cancer.